CNTB vs ABBV vs REGN

For growth investors, AbbVie Inc.

(ABBV) is the stronger pick with 8. 6% revenue growth year-over-year, versus 1. 0% for Regeneron Pharmaceuticals, Inc. (REGN). Regeneron Pharmaceuticals, Inc. (REGN) offers the better valuation at 17. 4x trailing P/E (15. 6x forward), making it the more compelling value choice. Analysts rate Connect Biopharma Holdings Limited (CNTB) a "Buy" — based on 5 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Regeneron Pharmaceuticals, Inc.

(REGN) is the cheapest at 17. 4x versus AbbVie Inc. at 86. 5x. On forward P/E, AbbVie Inc. is actually cheaper at 14. 4x — notably different from the trailing picture, reflecting expected earnings growth.

Over the past 5 years, AbbVie Inc.

(ABBV) delivered a total return of +102. 8%, compared to -84. 6% for Connect Biopharma Holdings Limited (CNTB). Over 10 years, the gap is even starker: ABBV returned +306. 7% versus CNTB's -86. 6%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Connect Biopharma Holdings Limited (CNTB) is the lower-risk stock at -0.

14β versus Regeneron Pharmaceuticals, Inc. 's 0. 81β — meaning REGN is approximately -682% more volatile than CNTB relative to the S&P 500. On balance sheet safety, Connect Biopharma Holdings Limited (CNTB) carries a lower debt/equity ratio of 0% versus 9% for Regeneron Pharmaceuticals, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), AbbVie Inc.

(ABBV) is pulling ahead at 8. 6% versus 1. 0% for Regeneron Pharmaceuticals, Inc. (REGN). On earnings-per-share growth, the picture is similar: Connect Biopharma Holdings Limited grew EPS 74. 1% year-over-year, compared to -0. 8% for AbbVie Inc.. Over a 3-year CAGR, REGN leads at 5. 6% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Regeneron Pharmaceuticals, Inc.

(REGN) is the more profitable company, earning 31. 4% net margin versus -60. 0% for Connect Biopharma Holdings Limited — meaning it keeps 31. 4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: ABBV leads at 32. 8% versus -86. 2% for CNTB. At the gross margin level — before operating expenses — CNTB leads at 100. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, AbbVie Inc.

(ABBV) trades at 14. 4x forward P/E versus 15. 6x for Regeneron Pharmaceuticals, Inc. — 1. 2x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for CNTB: 262. 9% to $9. 00.

In this comparison, ABBV (3.

2% yield), REGN (0. 5% yield) pay a dividend. CNTB does not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, AbbVie Inc.

(ABBV) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 34), 3. 2% yield, +306. 7% 10Y return). Both have compounded well over 10 years (ABBV: +306. 7%, REGN: +96. 0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: CNTB is a small-cap quality compounder stock; ABBV is a large-cap income-oriented stock; REGN is a mid-cap deep-value stock. ABBV pays a dividend while CNTB, REGN do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.